In solid malignant tumors, the role of the glucocorticoid receptor may range from beneficial to detrimental, and varies with the cancer type, the levels of the receptor, and the degree of crosstalk with other nuclear receptor family members that may drive a particular cancer (e.g., estrogen receptor in breast cancer, androgen receptor in prostate cancer)7. This evidence concerns the gene ESR1 and cancer.